Troxacitabine in leukemia

Ronan Swords, Effrosyni Apostolidou, Francis Giles

Research output: Contribution to journalReview article

Abstract

Troxacitabine (Troxatyl; BCH-4556; (-)-2′-deoxy-3′- oxacytadine) is the first synthetic L-nucleoside enantiomer to demonstrate broad spectrum cytotoxic activity. It was obtained by exchanging the sulphur endocyclic atom with oxygen in the structure of lamivudine, following the discovery that this agent had cytotoxic, as well as anti-viral activity. The unique "unnatural" stereochemistry of troxacitabine has produced impressive cytotoxic potency against a wide range of malignancies in the laboratory which led to its selection for clinical development. The initial trials with troxacitabine have established its efficacy in both solid and haematological malignancies, including those resistant to ara-C (cytarabine). This review will consider troxacitabine in terms of its pharmacology, mode of action, pharmacokinetics, toxicities, and clinical efficacy.

Original languageEnglish (US)
Pages (from-to)321-329
Number of pages9
JournalHematology
Volume11
Issue number5-6
DOIs
StatePublished - Oct 1 2006

    Fingerprint

ASJC Scopus subject areas

  • Hematology

Cite this

Swords, R., Apostolidou, E., & Giles, F. (2006). Troxacitabine in leukemia. Hematology, 11(5-6), 321-329. https://doi.org/10.1080/10245330601027316